Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status
Authors:
- Swan Swan LeongSLSwan Swan Leong
- Fei GaoFGFei Gao
- Chee Keong TohCTChee Keong Toh
- Wan Teck LimWLWan Teck Lim
- Eng Huat TanETEng Huat Tan
- Donald PoonDPDonald Poon
- 31 October 2010
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 76 (1) , 53-60
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are ElderlyJournal of Thoracic Oncology, 2007
- Comorbidity in patients with cancer: Prevalence and severity measured by cumulative illness rating scaleCritical Reviews in Oncology/Hematology, 2007
- Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer?Journal of Clinical Oncology, 2004
- Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and ControlJNCI: Journal of the National Cancer Institute, 2003
- Geriatric oncologyCritical Reviews in Oncology/Hematology, 2003
- Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinomaCancer, 2000
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1999
- Lung cancer in the elderlyEuropean Journal of Cancer, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- CUMULATIVE ILLNESS RATING SCALEJournal of the American Geriatrics Society, 1968